In a report released on January 14, Evan Seigerman from BMO Capital reiterated a Hold rating on Replimune Group, with a price target of $11.00. The company’s shares closed yesterday at $7.71.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in The Trade Desk Inc (Symbol: TTD), where a total of 69,953 contracts have traded so far, ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...

Thinking about learning Python? It’s a pretty popular language these days, and for good reason. It’s not super complicated, which is nice if you’re just starting out. We’ve put together a guide that ...

Microsoft is betting big on AI. Starting with integrating Bing with ChatGPT, it has implemented AI capabilities in its products. Microsoft Designer is a new product from Microsoft with AI capabilities ...

What if you could create your very own personal AI assistant—one that could research, analyze, and even interact with tools—all from scratch? It might sound like a task reserved for seasoned ...